M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 47 of 54
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
NCT00271505
Smoking Status and Body Image in Oral Cancer Patients
NCT00412490
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
NCT00267085
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
NCT00267059
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
NCT00569010
CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
NCT00270907
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
NCT00267046
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
NCT00491075
SRS Study in Patients With Non-Small Cell Lung Cancer
NCT00489008
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00255346
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
NCT00254423
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
NCT00253318
Melanoma Vaccine With Peptides and Leuprolide
NCT00254397
Folfox-B Study for Patients With Colorectal Liver Metastases
NCT00508872
Evaluation of Single Session Stereotactic Body Radiotherapy
NCT00492817
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
NCT00254384
Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas
NCT00495235
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
NCT00508326
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)
NCT00350818
Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
NCT00493350
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
NCT00493181
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
NCT00242502
Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy
NCT00499421
Treatment of Tumors of the Choroid Plexus Epithelium
NCT00500890
Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
NCT00507858
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
NCT00112502
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
NCT01031498
Evaluation of the Bio-Seal Biopsy Track Plug
NCT00527722
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
NCT00412581
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
NCT00338039
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
NCT00101010
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
NCT00508144
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
NCT00527982
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
NCT00227656
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
NCT00290498
Measuring Sleep Disturbance Among Cancer Patients
NCT00505544
Cancer Patients' Medication Knowledge in the Emergency Center
NCT00385476
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
NCT00147225
Gastrointestinal Stromal Tumors (GIST) Registry
NCT00507273
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
NCT00382590
Fatigue in Emergency Center Patients
NCT00504985
Phase II 5-Azacytidine Plus VPA Plus ATRA
NCT00326170
Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions
NCT00502580
Delirium Recall in Advanced Cancer Patients
NCT00493714
Effects of Rocking on Postoperative Ileus Duration Study
NCT00494806
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
NCT00385788
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
NCT00427791
A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast
NCT00147238
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
NCT00469144
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.